ScoreHaematology

CPSS-Mol in chronic myelomonocytic leukaemia

Clinical-molecular prognosis for CMML combining cytogenetics, four mutations and three clinical parameters.

Updated 31 October 2026

When to use it

Patients with CMML at diagnosis with karyotype and mutation panel, to estimate survival and AML transformation and assess transplant.

What it needs

  • Cytogenetic risk (CPSS)Options: Low (normal or −Y) · Intermediate (other abnormalities) · High (+8, chromosome 7 abnormality or complex)
  • ASXL1 mutationYes or no
  • NRAS mutationYes or no
  • RUNX1 mutationYes or no
  • SETBP1 mutationYes or no
  • Bone marrow blasts ≥ 5%Yes or no
  • White cell count ≥ 13 × 10⁹/LYes or no
  • Red cell transfusion dependenceYes or no

The points for each answer and the automatic total are in the app.

How to interpret it

Genetic risk group
ResultInterpretation
≤ 0Low (0)
1Intermediate-1 (1)
2Intermediate-2 (2)
≥ 3High (≥ 3)

In the app it also calculates: CPSS-Mol score.

Practical tip

CPSS cytogenetics: low risk = normal or −Y; high = trisomy 8, chromosome 7 abnormalities or complex karyotype; intermediate = all others.

3 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top